See more : PharmaEngine, Inc. (4162.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Softcat plc (SCT.L) Income Statement Analysis – Financial Results
- Toyota Motor Corporation (7203.T) Income Statement Analysis – Financial Results
- Sky Tower Public Company Limited (STOWER.BK) Income Statement Analysis – Financial Results
- Kyocera Corporation (KYOCF) Income Statement Analysis – Financial Results
- L’Air Liquide S.A. (AIQUF) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports